Hov­ione plots glob­al ex­pan­sion project, look­ing to boost ca­pac­i­ty on both sides of the At­lantic

Hov­ione is go­ing glob­al with its man­u­fac­tur­ing ex­pan­sion, from New Jer­sey all the way to Por­tu­gal.

The CD­MO an­nounced last week it would put $170 mil­lion in­to ex­pan­sions in Por­tu­gal, Ire­land and NJ, in an ef­fort to in­crease its glob­al ca­pac­i­ty by 25%. The move fol­lows an on­go­ing ef­fort since 2016 to ex­pand.

In a press re­lease, COO Jean-Luc Her­beaux said:

These in­vest­ments re­in­force our in­te­grat­ed spe­cial­ized of­fer glob­al­ly, pro­vid­ing our clients with a line of sight for their projects. Fo­cus is placed on fa­cil­i­tat­ing and speed­ing up the drug de­vel­op­ment cy­cle and launch, by pro­vid­ing API man­u­fac­tur­ing, Par­ti­cle En­gi­neer­ing and Tablet­ing ser­vices in each site. Our strat­e­gy con­tin­ues to be to grow or­gan­i­cal­ly via in­vest­ments in our ex­ist­ing sites, which are de­signed for pur­pose. This re­duces the com­plex­i­ty as­so­ci­at­ed with the growth jour­ney and al­lows us to fo­cus our man­age­ment at­ten­tion on what counts most, i.e. guar­an­tee­ing that our clients go to mar­ket with qual­i­ty, safe and ef­fec­tive med­i­cines for their pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER